2020 Dr. Sol J. Barer Award Honoree is Ken Frazier

On Nov 22, 2019

Named for Dr. Sol J. Barer, Founder and former Chairman and CEO of Celgene Corporation and former BioNJ Chairman, the Dr. Sol J. Barer Award for Vision, Innovation and Leadership recognizes outstanding research and business leaders who have made significant contributions to the growth and prosperity of the life sciences industry in New Jersey and throughout the world.

BioNJ honors Kenneth C. Frazier, chairman of the board and CEO of Merck & Co., Inc., as the 2020 Dr. Sol J. Barer Award for Vision, Innovation and Leadership recipient.

Frazier will be honored February 6, 2020 at BioNJ’s Annual Dinner Meeting & Innovation Celebration.

Frazier has served as the chairman of the board and CEO of Merck & Co., Inc. since 2011. Under his leadership, Merck is delivering innovative lifesaving medicines and vaccines, as well as long-term and sustainable value to its multiple stakeholders. Frazier has substantially increased Merck’s investment in research, including early research, while refocusing the organization on the launch and growth of key products that provide benefit to society. He has also led the formation of philanthropic and other initiatives that build on Merck’s 125-year plus legacy.

Frazier joined the company in 1992 and has held positions of increasing responsibility, including General Counsel and President. Prior to joining Merck, he was a Partner with the law firm of Drinker Biddle & Reath. Frazier’s contributions, especially in the legal, business and humanitarian fields, have been widely recognized. He sits on the boards of PhRMA, Weill Cornell Medicine, Exxon Mobil Corporation and Cornerstone Christian Academy in Philadelphia, PA. Frazier is also a member of the American Academy of Arts and Sciences, the American Philosophical Society, The Business Council, the Council of the American Law Institute and the American Bar Association.

“We are elated to honor Mr. Frazier with the 2020 Dr. Sol J. Barer Award for Vision, Innovation and Leadership for his tireless work on behalf of Patients, medical innovation and New Jersey’s ever-growing life sciences ecosystem,” said BioNJ President and CEO Debbie Hart. “Often described as ‘one of the most decent people in the industry,’ Mr. Frazier is highly respected from Washington to Wall Street for his business acumen, ability to navigate challenging political currents and commitment to transforming global health care.”

To access more business news, visit NJB News Now.

Related Articles: